[go: up one dir, main page]

KR970704428A - 활성성분의 선택적 방출을 제공하는 합성물(composition providing selective release of an active ingredient) - Google Patents

활성성분의 선택적 방출을 제공하는 합성물(composition providing selective release of an active ingredient) Download PDF

Info

Publication number
KR970704428A
KR970704428A KR1019970700903A KR19970700903A KR970704428A KR 970704428 A KR970704428 A KR 970704428A KR 1019970700903 A KR1019970700903 A KR 1019970700903A KR 19970700903 A KR19970700903 A KR 19970700903A KR 970704428 A KR970704428 A KR 970704428A
Authority
KR
South Korea
Prior art keywords
layer
active ingredient
rti
water
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1019970700903A
Other languages
English (en)
Inventor
빠웡 세쓰
안드레 스땀
Original Assignee
빠웡 세쓰
파르마 빠스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 빠웡 세쓰, 파르마 빠스 filed Critical 빠웡 세쓰
Publication of KR970704428A publication Critical patent/KR970704428A/ko
Withdrawn legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0002Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Furan Compounds (AREA)

Abstract

본 발명은 물에 불을 수 있는 물질인 코어(a)와, 탄력성이며 비수용성이며 투수성인 층(b)와, 하나 이상의 활성성분을 함유하는 층(c)과, 예정된 수성매체에서 투수성인 물질이며 코어의 팽창시에 분열될 수 있는 물질로 이루어진 층(d)과를 차례로 포함하여 구성된 합성물에 관한 것이다. 또한, 상기 합성물을 약품으로써 이용하는 것에 관한 것이다.

Description

활성성분의 선택적 방출을 제공하는 합성물(COMPOSITION PROVIDING ESLECTIVE RELEASE OF AN ACTIVE INGREDIENT)
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (11)

  1. 합성물에 있어서, (a) 물에 불을 수 있는 물질로 구성된 코어(1)와, (b)물을 통과시키고 물에 비수용성인 팽창력있는 물질로 이루어진 층(2)과, (c) 적어도 하나의 활성성분으로 구성되는층(3)과, (d)예정된 수성 매체에서 투수성(透水性)인 물질로 이루어지며, 코어(1)의 팽창의 결과로 분열될 수 있는층(4)과, 를 차례로 포함하여 구성된 것을 특징으로 하는 합성물.
  2. 제1항에 있어서, 상기 코어(1)는 50 내지 700%, 바람직하게는 100 내지500%, 더 바람직하게는 150 내지 300%의 부피팽창을 보여주는 것을 특징으로 하는 합성물.
  3. 제1또는 제2항에 있어서, 상기 합성물의 전체 무게에 기초하여, 합성물의 다양한 구성요소 (1) 내지 (4)의 무게의 상대적 비율은, (1)의 무게에 있어서는 30 내지 90%, 바람직하게는 50 내지70%, 더 바람직하게는 약 60%이며, (2)의 무게에 있어서는 1 내지 6%, 바람직하게는 2 내지 4%, 더 바람직하게는 약 3%이며,(3)의 무게에 있어서는 1 내지 60%, 바람직하게는 10 내지50%, 더 바람직하게는 약 30%이며, (4)의 무게에 있어서는 3 내지 15%, 바람직하게는 5 내지9%, 더 바람직하게는 약 7%인 것을 특징으로 하는 합성물.
  4. 제1내지 제3항 중 어느 한 항에 있어서, 예정된 수성매체에서 투수성이 있는 상기 층(4)의 물질은 수용성 중합체 물질이며, 상기 물질의 용해도는 pH에 의존하며, 상기 물질은 pH=6.0과 pH=8.0 사이로 구성된 pH값으로부터 시작하는 용해도를 갖는 것을 특징으로 하는 합성물.
  5. 제4항에 있어서, 상기 층(4)의 중합체 물질은 6.8의 pH값으로부터 시작하는 용해도를 나타내는 중합체 물질을 포함하여 구성된 것을 특징으로 하는 합성물.
  6. 제1항 내지 제5항 중 어느 한 항에 있어서, 상기 층 (4)의 물질은 위(胃) 내성 및 장(腸)용성 물질인 것을 특징으로 하는 합성물.
  7. 제1항 내지 제6항 중 어느 한 항에 있어서, 활성성분은 프레드니솔론 (predn isolon)이거나 약학적으로 수용가능한 그 유도체인 것을 특징으로 하는 합성물.
  8. 제1항 내지 제6항 중 어느 한 항에 있어서, 상기 층(3)은 1∼500㎎의 활성성분으로 이루어지며, 바람직하게는 5∼100㎎의 활성성분으로 이루어지는 것을 특징으로 하는 합성물.
  9. 제1항 내지 제8항 중 어느 한 항에 있어서, 약제로써 이용되는 것을 특징으로 하는 합성물.
  10. 제9항에 있어서, 결장의 병을 치료하기 위한 약제로써 이용되는 것을 특징으로 하는 합성물.
  11. 제1항 내지 제8항 중 어느 한 항에 따른 합성물을 준비하기 위한 방법에 있어서, (i) 가루형태위 혼합물에서 시작하여 압축된 코어(1)를 제공하는 단계와, (ii) 상기 코어 (1)를 한 층 (2) 코팅하는 단계와, (ⅲ) 상기 층(2)을 적어도 하나의 활성성분으로 구성된 층(3)으로 한 층 코팅하는 단계와, (ⅳ)상기 층(3)위에 한 층(4)을 코팅하는 단와를, 포함하는 것을 특징으로 하는 합성물 준비방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019970700903A 1994-08-11 1995-08-11 활성성분의 선택적 방출을 제공하는 합성물(composition providing selective release of an active ingredient) Withdrawn KR970704428A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9409963A FR2723536A1 (fr) 1994-08-11 1994-08-11 Composition permettant une liberation selective d'un principe actif
FR9409963 1994-08-11
PCT/FR1995/001079 WO1996004893A1 (fr) 1994-08-11 1995-08-11 Composition permettant une liberation selective d'un principe actif

Publications (1)

Publication Number Publication Date
KR970704428A true KR970704428A (ko) 1997-09-06

Family

ID=9466272

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019970700903A Withdrawn KR970704428A (ko) 1994-08-11 1995-08-11 활성성분의 선택적 방출을 제공하는 합성물(composition providing selective release of an active ingredient)

Country Status (14)

Country Link
US (1) US5824341A (ko)
EP (1) EP0774960A1 (ko)
JP (1) JPH10504300A (ko)
KR (1) KR970704428A (ko)
AU (1) AU698240B2 (ko)
CA (1) CA2197234A1 (ko)
CZ (1) CZ41297A3 (ko)
FI (1) FI970530A7 (ko)
FR (1) FR2723536A1 (ko)
HU (1) HUT77387A (ko)
NO (1) NO970610L (ko)
NZ (1) NZ290848A (ko)
PL (1) PL318586A1 (ko)
WO (1) WO1996004893A1 (ko)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5840332A (en) * 1996-01-18 1998-11-24 Perio Products Ltd. Gastrointestinal drug delivery system
FR2758459B1 (fr) * 1997-01-17 1999-05-07 Pharma Pass Composition pharmaceutique de fenofibrate presentant une biodisponibilite elevee et son procede de preparation
US6511477B2 (en) 1997-03-13 2003-01-28 Biocardia, Inc. Method of drug delivery to interstitial regions of the myocardium
US6322819B1 (en) * 1998-10-21 2001-11-27 Shire Laboratories, Inc. Oral pulsed dose drug delivery system
US6555139B2 (en) 1999-06-28 2003-04-29 Wockhardt Europe Limited Preparation of micron-size pharmaceutical particles by microfluidization
US6245913B1 (en) 1999-06-30 2001-06-12 Wockhardt Europe Limited Synthetic procedure for 5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methylthio]-IH-benzimidazole hydrochloride and its conversion to omeprazole
US20020131908A1 (en) * 2000-01-13 2002-09-19 George Benda Selective release apparatus for fluids
AR026148A1 (es) * 2000-01-21 2003-01-29 Osmotica Argentina S A Dispositivo osmotico con pasaje preformado que aumenta de tamano
US20030091634A1 (en) * 2001-09-14 2003-05-15 Pawan Seth Delayed release tablet of venlafaxin
US20030118647A1 (en) * 2001-12-04 2003-06-26 Pawan Seth Extended release tablet of metformin
US6913768B2 (en) * 2002-09-24 2005-07-05 Shire Laboratories, Inc. Sustained release delivery of amphetamine salts
US20040086567A1 (en) * 2002-10-30 2004-05-06 Pawan Seth Bioequivalent composition of itraconazole and a hydrophilic polymer
US20040162320A1 (en) * 2003-02-14 2004-08-19 Pawan Seth Solid composition containing nisoldipine a mixture of polyethylene oxides and an antioxidant
US20040249364A1 (en) * 2003-06-03 2004-12-09 Ilya Kaploun Device and method for dispensing medication to tissue lining a body cavity
US20060024362A1 (en) 2004-07-29 2006-02-02 Pawan Seth Composition comprising a benzimidazole and process for its manufacture
US8110226B2 (en) * 2007-07-20 2012-02-07 Mylan Pharmaceuticals Inc. Drug formulations having inert sealed cores
US20090036414A1 (en) * 2007-08-02 2009-02-05 Mutual Pharmaceutical Company, Inc. Mesalamine Formulations
CA2769760A1 (en) 2009-07-31 2011-02-03 Ranbaxy Laboratories Limited Multi-layered, multiple unit pharmaceutical compositions
US20140242158A1 (en) * 2011-09-30 2014-08-28 Astellas Pharma, Inc. Granular Pharmaceutical Composition
KR101384055B1 (ko) * 2012-02-02 2014-04-14 한국원자력연구원 버스트형 지연 방출 제어 조성물 및 이의 제조방법
WO2017146053A1 (ja) * 2016-02-23 2017-08-31 ニプロ株式会社 医薬組成物粒子とそれを含む口腔内崩壊製剤

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8518301D0 (en) * 1985-07-19 1985-08-29 Fujisawa Pharmaceutical Co Hydrodynamically explosive systems
DE3629994A1 (de) * 1986-09-03 1988-03-17 Weissenbacher Ernst Rainer Pro Vorrichtung zur medikamentenapplikation in koerperhoehlen bzw. auf koerperoberflaechen
US4968208A (en) * 1986-12-09 1990-11-06 Stig Eliasson Transporting arrangement for transporting motor vehicles
IT1230576B (it) * 1988-10-20 1991-10-28 Angeli Inst Spa Formulazioni farmaceutiche per via orale a liberazione selettiva nel colon
US5178868A (en) * 1988-10-26 1993-01-12 Kabi Pharmacia Aktiebolaq Dosage form
US5229131A (en) * 1990-02-05 1993-07-20 University Of Michigan Pulsatile drug delivery system
US5178866A (en) * 1990-03-23 1993-01-12 Alza Corporation Dosage form for delivering drug to the intestine
IE61651B1 (en) * 1990-07-04 1994-11-16 Zambon Spa Programmed release oral solid pharmaceutical dosage form
NZ286242A (en) * 1991-03-26 1997-11-24 Csl Ltd Use of veterinary implant as a single dose vaccination system: rupturable polymer film coating around core of active agent and water soluble excipient
JP2892858B2 (ja) * 1991-05-15 1999-05-17 田辺製薬株式会社 放出制御製剤およびその製造法
US5656296A (en) * 1992-04-29 1997-08-12 Warner-Lambert Company Dual control sustained release drug delivery systems and methods for preparing same
US5260069A (en) * 1992-11-27 1993-11-09 Anda Sr Pharmaceuticals Inc. Pulsatile particles drug delivery system
US5358502A (en) * 1993-02-25 1994-10-25 Pfizer Inc PH-triggered osmotic bursting delivery devices
DE4406424A1 (de) * 1994-02-28 1995-08-31 Bayer Ag Expandierbare Arzneiformen
US5536507A (en) * 1994-06-24 1996-07-16 Bristol-Myers Squibb Company Colonic drug delivery system
US5736159A (en) * 1995-04-28 1998-04-07 Andrx Pharmaceuticals, Inc. Controlled release formulation for water insoluble drugs in which a passageway is formed in situ
US5558879A (en) * 1995-04-28 1996-09-24 Andrx Pharmaceuticals, Inc. Controlled release formulation for water soluble drugs in which a passageway is formed in situ

Also Published As

Publication number Publication date
FR2723536A1 (fr) 1996-02-16
PL318586A1 (en) 1997-06-23
NZ290848A (en) 1998-03-25
NO970610L (no) 1997-03-21
NO970610D0 (no) 1997-02-10
FI970530A7 (fi) 1997-04-08
US5824341A (en) 1998-10-20
JPH10504300A (ja) 1998-04-28
EP0774960A1 (fr) 1997-05-28
WO1996004893A1 (fr) 1996-02-22
CZ41297A3 (cs) 1998-05-13
AU698240B2 (en) 1998-10-29
AU3169995A (en) 1996-03-07
FI970530A0 (fi) 1997-02-07
HUT77387A (hu) 1998-04-28
CA2197234A1 (fr) 1996-02-22

Similar Documents

Publication Publication Date Title
KR970704428A (ko) 활성성분의 선택적 방출을 제공하는 합성물(composition providing selective release of an active ingredient)
CA2204769A1 (en) Hemorrhoidal compositions and method of use
KR850007559A (ko) 조절 펩타이드의 삽입식 제형
GB2273657B (en) Preparation of solid microspheres or air-filled microcapsules
WO1996007398A3 (en) Sustained release of peptides from pharmaceutical compositions
KR900015734A (ko) 코어막 흡착 특성이 향상된, 약제학적으로 허용되는 활성성분을 함유하는 삼투성 연속 방출 경구 전달 시스템
DK1073415T3 (da) Gelerbare farmaceutiske sammensætninger
CA2316485A1 (en) Sustained-release pharmaceutical composition
ATE460921T1 (de) Medikamenthaltige zusammensetzung in aerosolform
IL133614A0 (en) Medicinal compositions for application to mucosa
CA2109623A1 (en) Process for solubilizing difficultly soluble pharmaceutical actives
CA2416403A1 (en) A medicinal aerosol formulation
JPS5528918A (en) Coating material
KR960000247A (ko) 사이클로스포린a 함유 조성물 및 그의 제조방법
FI86373B (fi) Belaeggning foer en farmaceutiskt tablett med foerdroejd effekt och foerfarande foer framstaellning av en tablett.
ATE271387T1 (de) Arzneizubereitungen enthaltend vitamin d und kalzium,ihre herstellung und therapeutische verwendung
GR1002907B (el) Επικαλυμμενο δισκιο μηλεινικης τριμεβουτινης
PL177710B1 (pl) Miejscowa kompozycja przeciwzapalna, sposób wytwarzania miejscowej kompozycji przeciwzapalnej i sposób rozpuszczania piroksikamu
ATE249224T1 (de) Oxytetracyclin enthaltendes arzneimittel mit verzögerter wirksoffabgabe
DE69808938D1 (de) Verfahren zur herstellung von pharmazeutischen zusammensetzungen
JPS5750914A (en) Betamethasone external pharmaceutical
ZA968762B (en) Derivatives of acid pyrazoles, their preparation process, their use as medicaments, their new use and the pharmaceutical compositions containing them.
KR900011455A (ko) 활성제의 서방형 제제 및 그 제조방법
KR930010579B1 (ko) 항진균성 겔제
KR960033450A (ko) 6,7-치환-2- 아미노테트랄린을 함유한 패혈증 쇼크 치료용 및 해열, 소염용 의약 조성물

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 19970211

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid